Green Alpha Advisors LLC Has $924,000 Stock Position in GSK plc (NYSE:GSK)

Green Alpha Advisors LLC raised its stake in GSK plc (NYSE:GSK) by 17.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,316 shares of the pharmaceutical company’s stock after purchasing an additional 4,107 shares during the quarter. Green Alpha Advisors LLC’s holdings in GSK were worth $924,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its position in shares of GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC increased its stake in shares of GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after purchasing an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC raised its holdings in shares of GSK by 20.0% in the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after purchasing an additional 83,433 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

Shares of NYSE GSK opened at $33.08 on Monday. GSK plc has a one year low of $32.83 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The firm has a market cap of $68.56 billion, a price-to-earnings ratio of 21.48, a P/E/G ratio of 1.52 and a beta of 0.63. The stock’s fifty day moving average price is $34.38 and its two-hundred day moving average price is $38.17.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were given a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.75%. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. GSK’s dividend payout ratio (DPR) is currently 95.45%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of recent analyst reports. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.